Navigation Links
Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
Date:1/17/2013

d to announce that the first patients are now enrolled in our Phase 3 HCVerso™ program, including at U.S. trial sites," said Peter Piliero , M.D., Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Patients infected with HCV may benefit most from an individualized treatment approach since a person's genetics, type of virus, and stage of liver disease vary from patient to patient. Our investigational interferon-free regimen has shown particular promise in treating patients with HCV genotype-1b so we have decided to enroll these patients in our Phase 3 trial program. Our goal is for an interferon-free future and ensuring patients are treated with the most effective treatment for them individually."

Results from the SOUND-C2 study, which were presented in November 2012 at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), found that up to 85 percent of patients infected with HCV GT-1b treated with Boehringer Ingelheim's investigational IFN-free regimen of faldaprevir, BI 207127 and ribavirin achieved viral cure at 12 and 24 weeks following treatment completion (SVR12 and SVR24).

Eliminating injectable interferon from treatment regimens is a critical goal in HCV as it can be difficult for patients to take due to long treatment duration and often severe side-effects. In addition, up to 50 percent of patients may not be eligible for treatment with interferon. Severe side-effects of interferon include heart failure, sepsis, leukopenia, depression and vision loss, resulting in adherence problems and treatment failure for many patients. Since 1999 there has been a significant increase in deaths due to chronic HCV, accounting for 15,000 deaths in the United States in 2007 alone.

"More effective and tolerable alternatives to interferon would help patients with their decision to start and
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
2. Boehringer Ingelheim Announces Equine Research Awards
3. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
4. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
5. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
6. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
7. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
8. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
9. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
10. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
11. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... WASHINGTON , Jan. 23, 2015  A new analysis ... Part D 2015 enrollment data shows that 81 percent ... convenient access and extra discounts at certain pharmacies. The ... "Preferred pharmacy plans are now the foundation of ...
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... 2011 Archimedes Pharma Ltd., and its subsidiary, Archimedes ... spray is now available by prescription in U.S. pharmacies. ... in cancer patients 18 years of age and older ... opioid therapy for their underlying persistent cancer pain. The ...
... Reportlinker.com announces that a new ... its catalogue: Bare ... Analysis, Competitive Landscape and Market Forecasts ... http://www.reportlinker.com/p0656885/Bare-Metal-Stents-BMS---Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices Bare Metal ...
Cached Medicine Technology:Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 2Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 3Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 4Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 5Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 6Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 7Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 13
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post ... insurance . , Purchasing an accidental death and dismemberment ... This type of rider provides benefits if the insured dies ... a lesser form of life insurance. , AD&D is ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... Colorado (PRWEB) January 22, 2015 Four years since ... Queen – which coincided with the marriage of Avasa & Matthew ... THE ROAD, which is scheduled for release through White Swan Records ... message that there is a sacred path available to all of ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... the October 15 issue of the Journal of Clinical ... (CASQ), a new self-completed instrument to measure excessive daytime ... C. Spilsbury, PhD, of the Division of Clinical Epidemiology ... of 411 adolescents between 11-17 years of age, who ...
... Oct. 15 With school schedules now routine and,the ... "not again",sighs. This might be a good time to ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071015/NYFNSL01 ) The following are ... lunch and snacks for greater nutritional impact. Add a,handful ...
... Gewurzmuller,s 2006 Sales Totalled US$ 65 M (About Euro 46 M),Frutarom Establishes its ... ... Field Frutarom Continues to Implement ... TASE: FRUT, OTC: FRUTF.PK) ("Frutarom") announced today,that it has signed an agreement to ...
... ,Real Women, Real Pain, Campaign Highlights the Suffering Caused ... the World Today, the International Association for the ... Against Pain in Women to draw attention to,the significant ... for more,effective care. Lack of awareness of pain issues ...
... Shows Nearly 1 in 3 Believe Nothing Can Be ... Crime as Greatest Risk to Well-Being, CHICAGO, Oct. ... can be done to prevent accidental injuries, posing a ... in the,United States, according to a national survey of ...
... study by Rhode Island Hospital and Brown University researchers reported ... not receive the initial psychiatric clearance for the surgery. The ... to clear candidates for surgery, and the largest to determine ... the reasons for exclusion. It was published in the October ...
Cached Medicine News:Health News:New tool to assess excessive daytime sleepiness in adolescents published in JCSM 2Health News:Fresh, Tasty - Healthy - Lunch and Snack Ideas 2Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 2Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 3Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 4Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 5Health News:International Association for the Study of Pain (IASP) Declares the Global Year Against Pain in Women 2Health News:International Association for the Study of Pain (IASP) Declares the Global Year Against Pain in Women 3Health News:Americans' Pessimistic View of Accident Prevention Poses Hurdle to Reducing Injuries, Survey Says 2Health News:Americans' Pessimistic View of Accident Prevention Poses Hurdle to Reducing Injuries, Survey Says 3Health News:1 in 5 bariatric surgery candidates not psychologically cleared for surgery 2
... IMMAGE Immunochemistry System gives you ... to perform accurate testing for ... It also delivers a wealth ... your laboratory to streamline its ...
... Array systems are fully automated ... fast turnaround of highly accurate ... drug monitoring (TDM) results. Using ... the easy-to-use Array® 360 performs ...
Inquire...
ELISA kit for detection of Rheumatoid Factor....
Medicine Products: